Epirubicin is a semisynthetic anthracycline antineoplastic agent that primarily acts as a topoisomerase II inhibitor, disrupting DNA replication and transcription. It also functions as a Foxp3 inhibitor to modulate regulatory T-cell activity, making it a valuable tool for oncology and immunology research in both in vitro and in vivo models.